PowerPoint Presentation PRESENTED AT THE FALL CLINICAL DERMATOLOGY CONFERENCE 2022 MEETING, OCTOBER 20–23, 2022, LAS VEGAS, NV, USA Figure 4. Areas Patients Reported Impacting Their Quality of Life Figure 3. Body Areas Patients Reported Most Affected by Psoriasis 0 20 40 60 80 100 Knees Arms Intertriginous areas Legs Elbows Scalp Patients (%) 56% 48% 41% 39% 33% 32% Figure 5. Most Common Areas Patients Reported Applying Topical Treatment Other areas include knees (25%), face (23%), groin (22%), armpits (20%), between the buttocks (19%), top of hands (19%), stomach folds (19%), under breasts (17%), and top of feet (17%). Figure 6. Patient Preferences for Treatment Types Figure 2. Patient-Reported Severity of Psoriasis Symptoms N=507 INTRODUCTION • Plaque psoriasis is a common inflammatory skin condition, affecting about 3% of US adults1 • A survey was conducted by the Harris Poll in the US, on behalf of Arcutis Biotherapeutics, to understand the perspectives and burden of patients with psoriasis who use topical treatments to manage their disease • This poster presents the results of this survey related to patient preferences and treatment patterns METHODS • The 20-minute online survey was conducted from October 21 through November 24, 2021, among 507 US adults diagnosed with psoriasis by a healthcare provider (Figure 1) • Participants had to use a topical treatment and not use a prescription injectable treatment for their psoriasis • Demographic variables included education, age by sex, race/ethnicity, census region, household size, and marital status • A propensity score variable was included to adjust for respondents’ propensity to be online • Raked weights were estimated using Random Iterative Method weighting RESULTS Patient-Reported Psoriasis Symptoms • At the time of diagnosis, most participants (N=507) described their psoriasis symptoms as moderate (59%; Figure 2) Patient-Reported Burden of Psoriasis • Participants estimated that an average of 15% of their bodies was affected by psoriasis – Most patients (63%) reported ≤10% of their body was affected – The body areas most often reported to be affected by psoriasis were the scalp, elbows, legs, intertriginous areas, arms, and knees (Figure 3) • Over 3 in 10 participants said they apply topical treatments to their elbows, scalp, legs, and arms (Figure 5) • Most (76%) participants preferred topical therapies for psoriasis, while 20% preferred pills and 4% preferred injections (Figure 6) • Most patients currently using topical treatments agreed to wanting more effective topical treatment options and a single topical therapy that can be used anywhere on the body (Figure 8) CONCLUSIONS • Patients with psoriasis want more effective and easier-to-use topical treatment options • While patients with psoriasis have used an average of 2.5 topical treatments, they prefer a single topical therapy that can be used anywhere on the body • Most respondents were open to using a new topical treatment for psoriasis and want a product that offers improvement of both plaques and itch April Armstrong,1 Melodie Young,2 Melissa Seal,3 Robert Higham,3 Teri Greiling4 1Keck School of Medicine, Department of Dermatology, University of Southern California, Los Angeles, CA, USA; 2Mindful Dermatology, Modern Research Associates, Dallas, TX, USA; 3Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA; 4Department of Dermatology, Oregon Health & Science University, Portland, OR, USA Patient Perspectives on the Prevalence and Burden of Psoriasis: Results From a National Survey of Adults With Psoriasis in the United States Mild Moderate Severe 59% 10% 31% • Participants reported psoriasis affecting the scalp, elbows, and legs caused the greatest impact on quality of life (Figure 4) 0 20 40 60 80 100 Legs Arms Scalp Elbows Patients (%) 39% 36% 30% 30% Patients’ Perspective of Psoriasis Treatment Options • 90% of participants agreed that they wished more effective topical treatment options were available (Figure 7) • 25% of participants were dissatisfied with the topical treatments they had used (Figure 7) Figure 7. Patient-Reported Desire for and Satisfaction With Topical Treatment Options Figure 8. Patient-Reported Wants From Topical Psoriasis Treatment 0 20 40 60 80 100 Instructions for using topical treatments were less confusing Topical treatment options were more tolerable Topical treatment with fewer safety concerns More topical treatment alternatives to steroids Topical treatments were once-daily application Use a single topical therapy anywhere on my body More effective topical treatment options Patients (%) 53% 78% 80% 81% 87% 90% 90% • Nearly all (89%) of participants said they are interested in trying a new topical treatment for psoriasis • The most common product attributes that participants want in a topical psoriasis treatment are improvement of plaques, itch relief, easy to apply, and safe to use (Figure 9) Figure 9. Patient-Reported Desired Attributes of Topical Psoriasis Treatment 0 20 40 60 80 100 Ability to use it on all affected areas Tolerable for skin Safe to use Easy to use Itch relief Improvement in plaques Patients (%) 68% 68% 63% 61% 47% 45% 0 20 40 60 80 100 Under breasts Stomach folds Knees Top of hands Between buttocks Arms Armpits Groin Face Legs Elbows Scalp 12% 12% 13% 13% 13% 14% 14% 15% 17% 19% 20% 39% Patients (%) Figure 1. Disposition of Patients With Psoriasis Using Topical Treatments N=507 Sex Women: 47% Men: 52% Mean age 46.3 years Mean number of treatment types ever used Topical: 2.5 Over the counter: 2.1 Prescription oral: 0.7 Topical Pills Injections 20% 4% 76% Str on gly ag re e So me wh at ag re e So me wh at di sa gr ee Str on gly di sa gr ee 0 20 40 60 80 100 54% 37% 8% 2% Pa ti en ts (% ) Desire for more effective topical treatment options Ve ry sa tis fie d So me wh at sa tis fie d So me wh at di ssa tis fie d Ve ry dis sa tis fie d 0 20 40 60 80 100 19% 6% 21% 54% Pa ti en ts (% ) Satisfaction with topical treatment options REFERENCE 1. Rachakonda TD, et al. J Am Acad Dermatol 2014;70:512–516. ACKNOWLEDGEMENTS • This study was supported by Arcutis Biotherapeutics, Inc. • Thank you to the investigators and their staff for their participation in the trial • We are grateful to the study participants and their families for their time and commitment • Writing support was provided by Lauren Ramsey, PharmD, Alligent Biopharm Consulting LLC, and funded by Arcutis Biotherapeutics, Inc. DISCLOSURES AA, MY, and TG are investigators and/or consultants for Arcutis Biotherapeutics, Inc. and received grants/research funding and/or honoraria; MS and RH are employees of Arcutis Biotherapeutics, Inc. Additional disclosures provided on request. Patient Perspectives on the Prevalence and Burden of Psoriasis: �Results From a National Survey of Adults With Psoriasis in the United States << /ASCII85EncodePages false /AllowTransparency false /AutoPositionEPSFiles true /AutoRotatePages /None /Binding /Left /CalGrayProfile (Dot Gain 20%) /CalRGBProfile (sRGB IEC61966-2.1) /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2) /sRGBProfile (sRGB IEC61966-2.1) /CannotEmbedFontPolicy /Warning /CompatibilityLevel 1.3 /CompressObjects /Off /CompressPages false /ConvertImagesToIndexed true /PassThroughJPEGImages true /CreateJobTicket false /DefaultRenderingIntent /Default /DetectBlends true /DetectCurves 0.0000 /ColorConversionStrategy /sRGB /DoThumbnails false /EmbedAllFonts true /EmbedOpenType false /ParseICCProfilesInComments true /EmbedJobOptions true /DSCReportingLevel 0 /EmitDSCWarnings false /EndPage -1 /ImageMemory 1048576 /LockDistillerParams false /MaxSubsetPct 100 /Optimize true /OPM 1 /ParseDSCComments true /ParseDSCCommentsForDocInfo true /PreserveCopyPage true /PreserveDICMYKValues true /PreserveEPSInfo true /PreserveFlatness false /PreserveHalftoneInfo false /PreserveOPIComments false /PreserveOverprintSettings true /StartPage 1 /SubsetFonts true /TransferFunctionInfo /Apply /UCRandBGInfo /Remove /UsePrologue false /ColorSettingsFile () /AlwaysEmbed [ true ] /NeverEmbed [ true ] /AntiAliasColorImages false /CropColorImages false /ColorImageMinResolution 300 /ColorImageMinResolutionPolicy /OK /DownsampleColorImages true /ColorImageDownsampleType /Bicubic /ColorImageResolution 600 /ColorImageDepth -1 /ColorImageMinDownsampleDepth 1 /ColorImageDownsampleThreshold 1.00000 /EncodeColorImages true /ColorImageFilter /DCTEncode /AutoFilterColorImages true /ColorImageAutoFilterStrategy /JPEG /ColorACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /ColorImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000ColorACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000ColorImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasGrayImages false /CropGrayImages false /GrayImageMinResolution 300 /GrayImageMinResolutionPolicy /OK /DownsampleGrayImages true /GrayImageDownsampleType /Bicubic /GrayImageResolution 450 /GrayImageDepth -1 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.00000 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /GrayImageDict << /QFactor 0.15 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /JPEG2000GrayACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000GrayImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasMonoImages false /CropMonoImages false /MonoImageMinResolution 1200 /MonoImageMinResolutionPolicy /OK /DownsampleMonoImages true /MonoImageDownsampleType /Bicubic /MonoImageResolution 600 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.00000 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict << /K -1 >> /AllowPSXObjects false /CheckCompliance [ /None ] /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly true /PDFXNoTrimBoxError false /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox false /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile (U.S. Web Coated \050SWOP\051 v2) /PDFXOutputConditionIdentifier (CGATS TR 001) /PDFXOutputCondition () /PDFXRegistryName (http://www.color.org) /PDFXTrapped /False /CreateJDFFile false /Description << /ENU ([Based on 'EPG UPLOAD'] [Based on 'EPG UPLOAD'] [Based on 'HighResolution_NoCrops'] [Based on 'HighResolution_NoCrops'] [Based on 'HighResolution_NoCrops\\0501\\051'] [Based on 'HighResolution_WithCrops'] [Based on '[PDF/X-1a:2001]'] Use these settings to create Adobe PDF documents that are to be checked or must conform to PDF/X-1a:2001, an ISO standard for graphic content exchange. For more information on creating PDF/X-1a compliant PDF documents, please refer to the Acrobat User Guide. Created PDF documents can be opened with Acrobat and Adobe Reader 4.0 and later.) >> /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ << /AsReaderSpreads false /CropImagesToFrames true /ErrorControl /WarnAndContinue /FlattenerIgnoreSpreadOverrides false /IncludeGuidesGrids false /IncludeNonPrinting false /IncludeSlug false /Namespace [ (Adobe) (InDesign) (4.0) ] /OmitPlacedBitmaps false /OmitPlacedEPS false /OmitPlacedPDF false /SimulateOverprint /Legacy >> << /AddBleedMarks false /AddColorBars false /AddCropMarks false /AddPageInfo false /AddRegMarks false /BleedOffset [ 0 0 0 0 ] /ConvertColors /ConvertToRGB /DestinationProfileName (sRGB IEC61966-2.1) /DestinationProfileSelector /UseName /Downsample16BitImages true /FlattenerPreset << /PresetSelector /HighResolution >> /FormElements false /GenerateStructure true /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles false /MarksOffset 0 /MarksWeight 0.250000 /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /DocumentCMYK /PageMarksFile /RomanDefault /PreserveEditing true /UntaggedCMYKHandling /UseDocumentProfile /UntaggedRGBHandling /LeaveUntagged /UseDocumentBleed false >> << /AllowImageBreaks true /AllowTableBreaks true /ExpandPage false /HonorBaseURL true /HonorRolloverEffect false /IgnoreHTMLPageBreaks false /IncludeHeaderFooter false /MarginOffset [ 0 0 0 0 ] /MetadataAuthor () /MetadataKeywords () /MetadataSubject () /MetadataTitle () /MetricPageSize [ 0 0 ] /MetricUnit /inch /MobileCompatible 0 /Namespace [ (Adobe) (GoLive) (8.0) ] /OpenZoomToHTMLFontSize false /PageOrientation /Portrait /RemoveBackground false /ShrinkContent true /TreatColorsAs /MainMonitorColors /UseEmbeddedProfiles false /UseHTMLTitleAsMetadata true >> ] >> setdistillerparams << /HWResolution [2400 2400] /PageSize [612.000 792.000] >> setpagedevice